Brainstorm Cell Therapeutics issues $143,750 note to Labrys Fund II, reports Q3 2025 results

BRAINSTORM CELL THERAPEUTICS INC.

Entered securities purchase agreement with Labrys Fund II for a promissory note of $143,750, including $18,750 original issue discount, receiving net proceeds of $121,500.
Note requires six payments of $22,589 starting May 2026, matures November 10, 2026, and is convertible at 25% discount to lowest trading price over 20 days, subject to 4.99% ownership cap.
Q3 2025 net loss was $2.1 million ($0.19 per share); cash and equivalents were $0.23 million as of September 30, 2025.
R&D expenses were $0.9 million and G&A expenses were $1.1 million, both down from prior year quarter.
FDA cleared Phase 3b ENDURANCE trial of NurOwn for ALS; a Citizen Petition was filed by ALS community representatives seeking renewed regulatory review.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. issued convertible note to Labrys Fund II, L.P. for principal amount of $143,750 (including $18,750 of original issue discount) and received funds of $121,500 after legal fees of $3,500.

Security: convertible note
Purchaser: Labrys Fund II, L.P.
Consideration: principal amount of $143,750 (including $18,750 of original issue discount) and received funds of $121,500 after legal fees of $3,500

Exact text from the filing

On November 10, 2025, Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Labrys Fund II, L.P., a Delaware limited partnership (“ Labrys ”), pursuant to which the Company issued to Labrys a promissory note (the “ Note ”) in the principal amount of $143,750 (including $18,750 of original issue discount) and received funds of $121,500 after legal fees of $3,500.

View on SEC.gov

Browse all equity issuances →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-112682

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.